482 related articles for article (PubMed ID: 21789621)
21. Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies.
Kikuchi T; Tsukada N; Kunisada K; Nomura-Yogo M; Oda Y; Sato K; Takei T; Ogura M; Abe Y; Suzuki K; Ishida T
Ann Hematol; 2023 Dec; 102(12):3489-3497. PubMed ID: 37668787
[TBL] [Abstract][Full Text] [Related]
22. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Dunavin NC; Wei L; Elder P; Phillips GS; Benson DM; Hofmeister CC; Penza S; Greenfield C; Rose KS; Rieser G; Merritt L; Ketcham J; Heerema N; Byrd JC; Devine SM; Efebera YA
Leuk Lymphoma; 2013 Aug; 54(8):1658-64. PubMed ID: 23194056
[TBL] [Abstract][Full Text] [Related]
23. Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
Mori S; Crawford BS; Roddy JV; Phillips G; Elder P; Hofmeister CC; Efebera Y; Benson DM
Hematol Oncol; 2012 Sep; 30(3):156-62. PubMed ID: 22028144
[TBL] [Abstract][Full Text] [Related]
24. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
Ludwig H; Beksac M; Bladé J; Cavenagh J; Cavo M; Delforge M; Dimopoulos M; Drach J; Einsele H; Facon T; Goldschmidt H; Harousseau JL; Hess U; Kropff M; Leal da Costa F; Louw V; Magen-Nativ H; Mendeleeva L; Nahi H; Plesner T; San-Miguel J; Sonneveld P; Udvardy M; Sondergeld P; Palumbo A
Oncologist; 2011; 16(4):388-403. PubMed ID: 21441574
[TBL] [Abstract][Full Text] [Related]
25. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
Stein R; Smith MR; Chen S; Zalath M; Goldenberg DM
Clin Cancer Res; 2009 Apr; 15(8):2808-17. PubMed ID: 19351768
[TBL] [Abstract][Full Text] [Related]
26. New therapies in multiple myeloma.
Merchionne F; Perosa F; Dammacco F
Clin Exp Med; 2007 Sep; 7(3):83-97. PubMed ID: 17972050
[TBL] [Abstract][Full Text] [Related]
27. Treatment Pattern and Outcome of Newly Diagnosed Multiple Myeloma Patients in a Resource-Limited Setting.
Cheong CS; Tengku K Aziz TAH; Anuar NA; Bee PC; Chin EFM; Khairullah S; Liong CC; Zamri Y; Gan GG
Asian Pac J Cancer Prev; 2024 Feb; 25(2):595-601. PubMed ID: 38415546
[TBL] [Abstract][Full Text] [Related]
28. Effect of Autologous Stem Cell Transplantation Combined with Modified VTD Regimen on Elderly Patients with Multiple Myeloma and Its Influence on miRNA Cytokines.
Bai Z; Shen J
Comput Math Methods Med; 2022; 2022():6320329. PubMed ID: 35222688
[TBL] [Abstract][Full Text] [Related]
29. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
Fonseca R; Usmani SZ; Mehra M; Slavcev M; He J; Cote S; Lam A; Ukropec J; Maiese EM; Nair S; Potluri R; Voorhees PM
BMC Cancer; 2020 Nov; 20(1):1087. PubMed ID: 33172403
[TBL] [Abstract][Full Text] [Related]
30. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Mateos MV; Gavriatopoulou M; Facon T; Auner HW; Leleu X; Hájek R; Dimopoulos MA; Delimpasi S; Simonova M; Špička I; Pour L; Kriachok I; Pylypenko H; Doronin V; Usenko G; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros AZ; Anderson LD; Bahlis NJ; Cavo M; Chai Y; Jeha J; Arazy M; Shah J; Shacham S; Kauffman MG; Richardson PG; Grosicki S
J Hematol Oncol; 2021 Apr; 14(1):59. PubMed ID: 33849608
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.
Prince HM; Adena M; Smith DK; Hertel J
Eur J Haematol; 2007 Aug; 79(2):93-9. PubMed ID: 17608711
[TBL] [Abstract][Full Text] [Related]
32. Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.
Lahoud OB; Landau H; Nguyen J; Devlin S; Lendvai N; Weltz J; Ayorinde T; Chung DJ; Lesokhin AM; Kewalramani T; Korde N; Mailankody S; Landgren O; Giralt S; Comenzo RL; Hassoun H
Leuk Lymphoma; 2022 Sep; 63(9):2126-2135. PubMed ID: 35648041
[TBL] [Abstract][Full Text] [Related]
33. Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients.
Abdrabou AK; Al Sharif F; El Fakih R; Zahrani HA; Al Yamany R; Saleh M; Alhayli S; Al Somali Z; Alotaibi A; AlShaibani A; Deeba F; Asif M; Ahmed SAOA; Al Fraih F; Shaheen M; Alahmari A; Rasheed W; Chaudhri NA; Al Mohareb F; Aljurf M; Hanbali A
Ann Saudi Med; 2024; 44(2):93-103. PubMed ID: 38615184
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity.
Decaux O; Clément M; Magrangeas F; Gouraud W; Charbonnel C; Campion L; Loiseau HA; Minvielle S
Cancer Sci; 2010 Apr; 101(4):889-97. PubMed ID: 20100206
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria.
Korubo KI; Madu AJ; Okoye HC; Nwogoh B
J Glob Oncol; 2018 Sep; 4():1-7. PubMed ID: 30241144
[TBL] [Abstract][Full Text] [Related]
36. Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients.
Strouse C; Mott SL; Smith BJ; Magalhaes-Silverman M; Farooq U; Zhan F; Jethava Y; Tricot G
Bone Marrow Transplant; 2024 Jan; 59(1):128-130. PubMed ID: 37816907
[No Abstract] [Full Text] [Related]
37. Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
Morè S; Corvatta L; Manieri VM; Saraceni F; Scortechini I; Mancini G; Fiorentini A; Olivieri A; Offidani M
Cells; 2022 Feb; 11(4):. PubMed ID: 35203257
[TBL] [Abstract][Full Text] [Related]
38. [Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma].
Ma Y; Xiao XB; Chen XL; Yuan SZ; Lu Y; Zhao SH; Chen JL; Shi GN; Wang YQ; Cheng NN; Feng P; Ding MS; Huang WR
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1016-1021. PubMed ID: 38503525
[No Abstract] [Full Text] [Related]
39. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.
Rosiñol L; Hebraud B; Oriol A; Colin AL; Ríos Tamayo R; Hulin C; Blanchard MJ; Caillot D; Sureda A; Hernández MT; Arnulf B; Mateos MV; Macro M; San-Miguel J; Belhadj K; Lahuerta JJ; Garelik MB; Bladé J; Moreau P
Front Oncol; 2023; 13():1197340. PubMed ID: 38023148
[TBL] [Abstract][Full Text] [Related]
40. A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma.
Becker PS; Gooley TA; Green DJ; Burwick N; Kim TY; Kojouri K; Inoue Y; Moore DJ; Nelli E; Dennie T; Bensinger WI
Blood Cancer J; 2016 May; 6(5):e422. PubMed ID: 27176798
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]